HLB LIFE SCIENCE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,950 KRW | -3.03% |
|
+1.19% | +48.03% |
| Mar. 22 | HLB Life Science to Raise 148.5 Billion Won via Shares Issuance; Shares Decline 8% | MT |
| Mar. 21 | HLB Life Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 624,336 | 1,305,844 | 1,280,316 | 1,188,951 | 1,077,864 | 1,165,599 |
| Enterprise Value (EV) 1 | 523,242 | 1,142,063 | 1,133,674 | 1,053,611 | 1,093,896 | 1,253,317 |
| P/E ratio | -27.1 x | -161 x | -22.9 x | -23.9 x | -18.7 x | -197 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.09 x | 11.5 x | 13.9 x | 22.2 x | 10.8 x | 11.9 x |
| EV / Revenue | 5.11 x | 10 x | 12.3 x | 19.7 x | 11 x | 12.8 x |
| EV / EBITDA | -70.4 x | -329 x | -197 x | -66.5 x | -74.3 x | -70.4 x |
| EV / FCF | -26.8 x | -46.1 x | -53.4 x | -101 x | -32 x | -42.5 x |
| FCF Yield | -3.73% | -2.17% | -1.87% | -0.99% | -3.12% | -2.35% |
| Price to Book | 3.06 x | 3.91 x | 4.46 x | 4.83 x | 4.59 x | 5.3 x |
| Nbr of stocks (in thousands) | 76,350 | 98,980 | 99,008 | 100,435 | 101,685 | 101,799 |
| Reference price 2 | 8,177 | 13,193 | 12,931 | 11,838 | 10,600 | 11,450 |
| Announcement Date | 3/18/19 | 3/18/20 | 3/23/21 | 3/23/22 | 3/23/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 102,476 | 114,019 | 91,797 | 53,494 | 99,591 | 97,990 |
| EBITDA 1 | -7,431 | -3,475 | -5,763 | -15,845 | -14,727 | -17,797 |
| EBIT 1 | -7,777 | -5,377 | -8,018 | -18,329 | -19,950 | -25,493 |
| Operating Margin | -7.59% | -4.72% | -8.73% | -34.26% | -20.03% | -26.02% |
| Earnings before Tax (EBT) 1 | -18,395 | 8,564 | -56,490 | -53,624 | -60,839 | -6,503 |
| Net income 1 | -18,191 | 7,520 | -55,797 | -49,152 | -54,277 | -5,983 |
| Net margin | -17.75% | 6.6% | -60.78% | -91.88% | -54.5% | -6.11% |
| EPS 2 | -302.0 | -81.77 | -563.6 | -494.8 | -565.3 | -58.00 |
| Free Cash Flow 1 | -19,491 | -24,761 | -21,225 | -10,410 | -34,143 | -29,493 |
| FCF margin | -19.02% | -21.72% | -23.12% | -19.46% | -34.28% | -30.1% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/18/19 | 3/18/20 | 3/23/21 | 3/23/22 | 3/23/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 16,032 | 87,718 |
| Net Cash position 1 | 101,095 | 163,782 | 146,642 | 135,340 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -1.089 x | -4.929 x |
| Free Cash Flow 1 | -19,491 | -24,761 | -21,225 | -10,410 | -34,143 | -29,493 |
| ROE (net income / shareholders' equity) | -14.2% | 2.8% | -17.9% | -18.4% | -22.5% | -2.53% |
| ROA (Net income/ Total Assets) | -2.07% | -0.87% | -1.37% | -3.83% | -3.65% | -3.81% |
| Assets 1 | 879,780 | -868,407 | 4,076,038 | 1,282,898 | 1,485,710 | 156,843 |
| Book Value Per Share 2 | 2,671 | 3,373 | 2,901 | 2,451 | 2,308 | 2,160 |
| Cash Flow per Share 2 | 221.0 | 371.0 | 375.0 | 311.0 | 305.0 | 157.0 |
| Capex 1 | 386 | 9,077 | 8,410 | 2,421 | 10,676 | 20,618 |
| Capex / Sales | 0.38% | 7.96% | 9.16% | 4.53% | 10.72% | 21.04% |
| Announcement Date | 3/18/19 | 3/18/20 | 3/23/21 | 3/23/22 | 3/23/23 | 3/20/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +48.03% | 1.32B | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B |
- Stock Market
- Equities
- A067630 Stock
- Financials HLB Life Science Co., Ltd.
